Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
Dexcom Inc (DXCM) is a leader in continuous glucose monitoring systems, transforming diabetes care through real-time health data solutions. This page consolidates official announcements, financial updates, and strategic developments for stakeholders tracking the company’s progress in medical technology.
Access timely updates on product innovations, regulatory milestones, and partnership agreements that shape Dexcom’s position in the diabetes management sector. Investors will find earnings reports and market analyses, while healthcare professionals can monitor clinical trial outcomes and device enhancements.
Key content includes FDA clearances, international expansion updates, and technology integration developments with insulin delivery systems. All materials are sourced from verified channels to ensure reliability for research and decision-making.
Bookmark this page for streamlined access to Dexcom’s latest advancements in CGM technology and related financial performance. Check regularly for critical updates that impact both patient care and investment considerations.
Dexcom (NASDAQ: DXCM) announced the expansion of coverage for its Dexcom G7 Continuous Glucose Monitoring (CGM) System under Ontario's Drug Benefit (ODB) program. The coverage now extends to eligible Ontarians managing diabetes with insulin, impacting a significant portion of the estimated 1.7 million people living with diabetes in Ontario.
The Dexcom G7, recognized as the most accurate CGM and the #1 preferred glucose sensor by Canadian endocrinologists, offers unique features including a predictive urgent low alert, waterproof sensor, 30-minute warm-up time, and direct Apple Watch functionality. The expanded coverage makes Dexcom G7 the most covered CGM on government-funded programs in Ontario, available through ODB, ADP, private insurance, and NIHB programs.
Dexcom (NASDAQ:DXCM), the global leader in glucose biosensing, has launched a groundbreaking AI-powered Smart Food Logging feature across its product portfolio. The feature is now available on both Stelo, the first FDA-cleared over-the-counter glucose biosensor, and Dexcom G7, making it the only prescription continuous glucose monitor in the U.S. with photo logging capability.
The innovative feature allows users to simply take a photo of their food in the app, where AI automatically identifies ingredients and populates meal descriptions. This launch is accompanied by several other technological enhancements, including Weekly Insights powered by GenAI, Oura integration for holistic biometric tracking, customizable target ranges in Dexcom G7, and a new Glucose Impact feature for better understanding of how various activities affect glucose levels.
Users can access these features by updating to the latest version of their respective apps on iOS and Android platforms.Dexcom (NASDAQ:DXCM) has announced the fourth season of its groundbreaking Dexcom U NIL program, exclusively for college athletes with diabetes. The 2025 roster features 21 total athletes, including 13 new members and 8 returning participants from various colleges across the United States.
The company hosted its first-ever Dexcom U Signing Day Camp in Baltimore, featuring Baltimore Ravens tight end Mark Andrews and NFL legend Mike Golic Sr. The program, launched in 2022, has impacted over 40 college athletes across 38 schools and 19 sports. All participants use Dexcom's continuous glucose monitoring (CGM) technology to manage their diabetes while competing at the collegiate level.
DexCom (NASDAQ:DXCM) has scheduled its second quarter 2025 earnings release and conference call for July 30, 2025. The company will release its financial results after market close, followed by a management conference call at 4:30 p.m. Eastern Time to review the quarterly performance.
Investors can access the conference call by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using confirmation ID "9430114". A concurrent webcast will be available on the Dexcom investor relations website at investors.dexcom.com, where it will also be archived for future reference.
Dexcom (NASDAQ: DXCM), a leader in real-time continuous glucose biosensing, has promoted Jake Leach to the role of president while maintaining his position as chief operating officer. Leach, who has over 21 years of leadership experience at Dexcom, has been instrumental in developing the company's biosensing platforms since their first commercial system launch.
In his COO role, which he has held since 2022, Leach oversees product development, global operations, R&D, quality management, regulatory and medical affairs. His expanded role as president will include additional oversight of Dexcom's corporate development and strategy efforts. CEO Kevin Sayer expressed strong confidence in Leach's ability to build upon his track record of innovation and achievement in metabolic health.
DexCom (DXCM) reported strong Q1 2025 financial results with revenue growing 12% year-over-year to $1.036 billion. The company saw U.S. revenue growth of 15% and international revenue growth of 7%. GAAP operating income reached $133.7 million, representing 12.9% of revenue.
Key developments include broader coverage with 2 of 3 largest PBMs now covering Dexcom CGM for diabetes patients, Stelo's launch on Amazon, and FDA clearance for the Dexcom G7 15 Day System. The company announced a $750 million share repurchase program and updated its 2025 guidance, projecting revenue of $4.60 billion (14% growth) with Non-GAAP Operating Margin of approximately 21%.
Dexcom (NASDAQ: DXCM) has announced the fourth season of Dexcom U, its unique Name, Image and Likeness (NIL) program for college athletes with diabetes. The program is launching its first nationwide search for new athletes to join its 2025 roster, with nominations open through May 23.
Selected athletes will join eight returning members at the Dexcom U Signing Day Camp this summer, hosted by Baltimore Ravens tight end Mark Andrews. Participants will receive access to Dexcom Continuous Glucose Monitoring (CGM) technology, exclusive events, and networking opportunities with collegiate and professional athletes.
The program aims to showcase athletes who manage diabetes while competing at high levels, using Dexcom G7 technology to monitor their glucose levels in real-time through smartphones and smartwatches. The selection committee will focus on candidates who can serve as role models and share inspiring stories with the next generation of youth athletes.
Dexcom (NASDAQ:DXCM) has received FDA clearance for its Dexcom G7 15 Day Continuous Glucose Monitoring System for people over 18 with diabetes in the United States. The new system boasts an impressive 15.5 days of wear time and superior accuracy with an overall MARD of 8.0%.
Key features include waterproof capability, direct Apple Watch connectivity, automated activity logging, and a 12-hour grace period for sensor replacement. The system also offers remote glucose sharing with caregivers and enhanced alert settings.
The company plans to launch Dexcom G7 15 Day in the second half of 2025 and is working with insulin pump partners to ensure compatibility with automated insulin delivery systems. Clinical data presented at the Advanced Technologies and Treatments for Diabetes conference in Amsterdam confirms G7 15 Day as the most accurate CGM for adults.
DexCom (NASDAQ:DXCM) has announced its upcoming first quarter 2025 earnings release and conference call schedule. The company will disclose its Q1 2025 financial results after market close on Thursday, May 1, 2025.
Management will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the quarterly performance. Investors can access the call by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using confirmation ID '9430114'. A concurrent webcast will be available on the Dexcom investor relations website at investors.dexcom.com, where it will also be archived for future reference.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
